Liliane Tenenbaum

List of Publications by Year
in descending order

55 papers	2,187 citations	257357 24 h-index	233338 45 g-index
56 all docs	56 docs citations	56 times ranked	2984 citing authors

#	Article	IF	Citations
1	Selective targeting of striatal parvalbumin-expressing interneurons for transgene delivery. Journal of Neuroscience Methods, 2021, 354, 109105.	1.3	5
2	CDNF: An innovative actor in disease-modifying approaches for Parkinsonâ€™s disease. Molecular Therapy, 2021, 29, 2634-2636.	3.7	1
3	MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients. Molecular Psychiatry, 2020, 25, 2889-2904.	4.1	76
4	Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase <scp>II</scp> Trial. Movement Disorders, 2020, 35, 1323-1335.	2.2	16
5	GDNF, A Neuron-Derived Factor Upregulated in Glial Cells during Disease. Journal of Clinical Medicine, 2020, 9, 456.	1.0	53
6	Combining Gene Transfer and Nonhuman Primates to Better Understand and Treat Parkinsonâ€™s Disease. Frontiers in Molecular Neuroscience, 2019, 12, 10.	1.4	14
7	Regulated viral BDNF delivery in combination with Schwann cells promotes axonal regeneration through capillary alginate hydrogels after spinal cord injury. Acta Biomaterialia, 2017, 60, 167-180.	4.1	93
8	59.2 Matrix Metalloproteinase Inhibition Prevents the Adult Excitatory-Inhibitory Imbalance Induced by the Reciprocal Interaction Between Neuroinflammation and Oxidative Stress During Development. Schizophrenia Bulletin, 2017, 43, S32-S32.	2.3	1
9	Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms. Frontiers in Neuroanatomy, 2017, 11, 29.	0.9	51
10	Tet-On Systems For Doxycycline-inducible Gene Expression. Current Gene Therapy, 2016, 16, 156-167.	0.9	253
11	A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16027.	1.8	32
12	610. An Inducible AAV Vector Mediating GDNF Signal Transduction at Clinically-Acceptable Sub-Antimicrobial Doxycycline Doses. Molecular Therapy, 2016, 24, S242.	3.7	0
13	Effect of SOCS1 overexpression on RPE cell activation by proinflammatory cytokines. Neuroscience Letters, 2016, 630, 209-215.	1.0	2
14	Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system. Neurobiology of Disease, 2016, 88, 44-54.	2.1	20
15	Mild guanidinoacetate increase under partial guanidinoacetate methyltransferase deficiency strongly affects brain cell development. Neurobiology of Disease, 2015, 79, 14-27.	2.1	37
16	Intracisternal delivery of NFÃŽÂºB-inducible scAAV2/9 reveals locoregional neuroinflammation induced by systemic kainic acid treatment. Frontiers in Molecular Neuroscience, 2014, 7, 92.	1.4	7
17	Manufacturing and Characterization of a Recombinant Adeno-Associated Virus Type 8 Reference Standard Material. Human Gene Therapy, 2014, 25, 977-987.	1.4	80
18	Biosafety of Recombinant Adeno-associated Virus Vectors. Current Gene Therapy, 2014, 13, 434-452.	0.9	77

#	Article	IF	Citations
19	A next step in adenoâ€associated virusâ€mediated gene therapy for neurological diseases: regulation and targeting. British Journal of Clinical Pharmacology, 2013, 76, 217-232.	1.1	28
20	An Adeno-Associated Virus-Based Intracellular Sensor of Pathological Nuclear Factor-ÎºB Activation for Disease-Inducible Gene Transfer. PLoS ONE, 2013, 8, e53156.	1.1	9
21	Rapid Transgene Expression in Multiple Precursor Cell Types of Adult Rat Subventricular Zone Mediated by Adeno-Associated Type 1 Vectors. Human Gene Therapy, 2012, 23, 742-753.	1.4	17
22	Recombinant AAV Delivery to the Central Nervous System. Methods in Molecular Biology, 2012, 807, 159-177.	0.4	10
23	Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery. Cancer Immunology, Immunotherapy, 2011, 60, 273-281.	2.0	25
24	Development of a Liver-specific Tet-On Inducible System for AAV Vectors and Its Application in the Treatment of Liver Cancer. Molecular Therapy, 2011, 19, 1245-1253.	3.7	51
25	Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard Material. Human Gene Therapy, 2010, 21, 1273-1285.	1.4	125
26	Reversible neurochemical changes mediated by delayed intrastriatal glial cell lineâ€derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model. Journal of Gene Medicine, 2009, 11, 899-912.	1.4	37
27	Differential Transgene Expression Profiles in Rat Brain, Using rAAV2/1 Vectors with Tetracycline-Inducible and Cytomegalovirus Promoters. Human Gene Therapy, 2008, 19, 1293-1306.	1.4	15
28	Differential transgene expression profiles from rAAV2/1 vectors using the tetON and CMV promoters in the rat brain.. Human Gene Therapy, 2008, .	1.4	1
29	Recombinant AAV viral vectors serotype 1, 2, and 5 mediate differential gene transfer efficiency in rat striatal fetal grafts. Cell Transplantation, 2008, 16, 1013-20.	1.2	4
30	Overexpression of mouse IsK protein fused to green fluorescent protein induces apoptosis of human astroglioma cells. Neurological Research, 2007, 29, 628-631.	0.6	1
31	Recombinant AAV Viral Vectors Serotype 1, 2, and 5 Mediate Differential Gene Transfer Efficiency in Rat Striatal Fetal Grafts. Cell Transplantation, 2007, 16, 1013-1020.	1.2	6
32	Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. Experimental Neurology, 2007, 204, 387-399.	2.0	47
33	243. Control of Undesirable Effects of GDNF Delivered in the Striatum of Healthy Rats Using a Tetracycline-Inducible AAV1 Vector. Molecular Therapy, 2006, 13, S93.	3.7	0
34	Efficiency of adeno-associated virus type-2 vectors in non-human primate Schwann cells. NeuroReport, 2005, 16, 1757-1762.	0.6	3
35	Minocycline in phenotypic models of Huntington's disease. Neurobiology of Disease, 2005, 18, 206-217.	2.1	52
36	Efficient Early and Sustained Transduction of Human Fetal Mesencephalon Using Adeno-Associated Virus Type 2 Vectors. Cell Transplantation, 2004, 13, 565-572.	1.2	5

#	Article	IF	Citations
37	Recombinant AAV-mediated gene delivery to the central nervous system. Journal of Gene Medicine, 2004, 6, S212-S222.	1.4	180
38	Rescue and sprouting of motoneurons following ventral root avulsion and reimplantation combined with intraspinal adeno-associated viral vector-mediated expression of glial cell line-derived neurotrophic factor or brain-derived neurotrophic factor. Experimental Neurology, 2004, 189, 303-316.	2.0	119
39	Clinical potential of minocycline for neurodegenerative disorders. Neurobiology of Disease, 2004, 17, 359-366.	2.1	145
40	Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Therapy, 2003, 10, 84-94.	2.3	91
41	Minocycline-induced activation of tetracycline-responsive promoter. Neuroscience Letters, 2003, 352, 155-158.	1.0	15
42	Virus Vectors for use in the Central Nervous System. International Review of Neurobiology, 2003, 55, 65-98.	0.9	1
43	Evaluation of Risks Related to the Use of Adeno-Associated Virus-Based Vectors. Current Gene Therapy, 2003, 3, 545-565.	0.9	132
44	AAV2 vectors mediate efficient and sustained transduction of rat embryonic ventral mesencephalon. NeuroReport, 2002, 13, 1503-1507.	0.6	9
45	Neuroprotective gene therapy for Parkinson's disease. Current Gene Therapy, 2002, 2, 451-483.	0.9	23
46	Tropism of AAV-2 vectors for neurons of the globus pallidus. NeuroReport, 2000, 11, 2277-2283.	0.6	38
47	Cellular contaminants of adeno-associated virus vector stocks can enhance transduction. Gene Therapy, 1999, 6, 1045-1053.	2.3	26
48	Plastic phenotype of human oligodendroglial tumour cells in vitro. Neuropathology and Applied Neurobiology, 1996, 22, 302-310.	1.8	12
49	Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different tissue origins and its expression therein. Journal of Virology, 1994, 68, 1397-1406.	1.5	37
50	Inhibition of Heterologous DNA Replication by the MVMp Nonstructural NS-1 Protein: Identification of a Target Sequence. Virology, 1993, 197, 630-641.	1.1	13
51	Genotoxic potency of monofunctional alkylating agents in E. coli: comparison with carcinogenic potency in rodents. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1990, 228, 177-185.	0.4	12
52	The E. coli multitest: a set of strains to characterize diverse genotoxic effects. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1988, 203, 415-426.	0.4	7
53	Quantification of the genotoxic effects of alkylating agents in bacterial assays. Mutagenesis, 1988, 3, 317-322.	1.0	3
54	recA-independent mutagenicity induced by chloroethylene oxide in E. coli. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1985, 152, 157-159.	0.4	10

#	Article	IF	Citations
55	A system for detection of genetic and epigenetic alterations in Escherichia coli induced by DNA-damaging agents. Journal of Molecular Biology, 1985, 186, 97-105.	2.0	59